MaxCyte, Inc. Stock Analysis & AI Score
MaxCyte, Inc. (MXCT) has an ST Score of 56.9 (B-), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $6.00 price target (+404.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
MaxCyte, Inc. (MXCT) has an ST Score of 56.9 (B-), driven by its Forecast (A) and held back by its Growth (C-). Analysts rate it Buy with a $6.00 price target (+404.2% upside).
- Strongest
- ForecastA
- Weakest
- GrowthC-
All factor grades
- ForecastA
- ProfitabilityA-
- ValuationB+
- Financial StrengthB
- MomentumC+
- GrowthC-
- Piotroski2/9
Contact
MXCT stock: frequently asked questions
What is MXCT's ST Score?
MaxCyte, Inc. (MXCT) has an ST Score of 56.9 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MXCT a buy, hold, or sell?
Analysts rate MXCT a Buy, with a price target of $6.00 (+404.2% vs the current price). Our ST Score grades it B- (56.9/100). The ST Score is a data-driven signal, not a recommendation.
What are MXCT's factor grades?
Valuation B+, Profitability A-, Financial Strength B, Momentum C+, Growth C-, Forecast A.
What is MXCT's valuation grade?
MaxCyte, Inc. (MXCT) earns a valuation grade of B+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MXCT's growth grade?
MaxCyte, Inc. (MXCT) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MXCT's profitability grade?
MaxCyte, Inc. (MXCT) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MXCT's financial strength grade?
MaxCyte, Inc. (MXCT) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MXCT?
The average analyst price target for MaxCyte, Inc. (MXCT) is $6.00 from 6 analysts, which is +404.2% versus the recent price of $1.19.
What is MXCT's Piotroski score?
MaxCyte, Inc. (MXCT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.